Role of Activated Charcoal in Decreasing Blood Urea, Creatinine and Phosphorous

Assiut University

Status and phase: Unknown; Phase 2

Conditions: Chronic Kidney Disease stage3

Treatments: Drug: Activated charcoal; Dietary Supplement: Dry seeds

Study type: Interventional

Funder types: Other

Identifiers

NCT04311645

Charcoal CKD progression

Details and patient eligibility

About

The study aims to explore the ability of Oral activated charcoal to adsorb uremic toxins limiting the progression of chronic kidney disease and delaying the need for hemodialysis in patients with CKD stages III and IV.

To compare its effect with the effect of dry seeds as absorbents of uremic toxins

Full description

In recent years, chronic kidney disease(CKD) has become a worldwide public health issue.

The main factors affecting the prognosis of patients with chronic kidney disease are its complications, including cardiovascular and cerebrovascular diseases, malnutrition, inflammation, atherosclerosis syndrome, and anemia.

The accumulation of uremic toxins, such as indoxyl sulfate and p-cresyl sulfate, is implicated in the progression of renal failure and cardiovascular disease.

For many patients, chronic kidney disease (CKD) is a progressive condition marked by deteriorating renal function ultimately leading to end-stage renal disease (ESRD) and many patients refuse to start chronic hemodialysis.

Therapeutic approaches that decrease the level of uremic toxins are a rational method for inhibiting this progression.

Many researches have been done aiming to find alternatives for chronic hemodialysis either for economic issues or psychological issues especially in elderly patients, as example:

• Gum Arabic in the remedy and amelioration of kidney dysfunction and end-stage renal disease
• skin as excretory root for urea, increasing sweat from sweat glands can support kidney function by excreting a good amount of what kidneys naturally excrete.
• The oral charcoal adsorbent reduces serum levels of indoxyl sulfate through adsorption of indole converted from dietary tryptophan in the gastrointestinal tract decreasing serum creatinine and urea level .

In this study, the clinical data supporting the role of oral activated charcoal in a dose of 30gm/ day for slowing the progression of CKD will be reviewed.

In this study, a trial will be done using dry seeds (lentils as an example) as an absorbent for uremic toxins comparing its effect with the effect of oral activated charcoal.

Enrollment: 90 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients with CKD stages iii and iv

Patients with age more than 18 years old

Exclusion criteria

Patients on regular hemodialysis

Patients with age less than 18 years old

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

90 participants in 3 patient groups

1st group

Other group

Description:

Oral activated charcoal in a dose of 30 gm/day

Treatment:

Drug: Activated charcoal

2nd group

Other group

Description:

Dry seeds in a dose of 1 gm/ day

Treatment:

Dietary Supplement: Dry seeds

3rd group

No Intervention group

Description:

control group